Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital
about
Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agentAmbulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole).Detection of novel mutations in the gyrA gene of Staphylococcus aureus by nonradioisotopic single-strand conformation polymorphism analysis and direct DNA sequencing.Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacinLevofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin.Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolonesIn vivo therapeutic efficacies of PD 138312 and PD 140248, two novel fluoronaphthyridines with outstanding gram-positive potency.Inducible NorA-mediated multidrug resistance in Staphylococcus aureus.Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group.Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene.Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.In vitro activities of new antimicrobial agents against multiresistant Staphylococcus aureus isolated from septicemic patients during a Belgian national survey from 1983 to 1985.Synergistic effect of quinolones and oxacillin on methicillin-resistant Staphylococcus speciesSynergy of levofloxacin (L-ofloxacin) and oxacillin against quinolone-resistant Staphylococcus aureus, measured by the time-kill method.Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus.In vivo selection during pefloxacin therapy of a mutant of Staphylococcus aureus with two mechanisms of fluoroquinolone resistance.In vitro antistaphylococcal activities of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with those of ciprofloxacin, mupirocin (pseudomonic acid), and peptide-class antimicrobial agents.Influence of rifampin on fleroxacin pharmacokinetics.Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureusIn vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency.Occurrence of quinolone resistance in Staphylococcus aureus from nosocomial infection.Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditisActivity of new quinolones against ciprofloxacin-resistant staphylococciEmergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario, CanadaCiprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis.Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers.Comparison between the effect of Lawsonia inermis and flubendazole on Strongyloides species using scanning electron microscopyA review of the antimicrobial activity of the fluoroquinolones.Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureusImproved bactericidal activity of Q-35 against quinolone-resistant staphylococci.Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.
P2860
Q28335923-51DA104F-590E-4B3D-85BD-D1A51D9F40D1Q33702686-FD361ED3-C4A8-4B8A-B2C7-9ADBB4B378E8Q33750373-EDBC2D2D-E3B6-43F7-A463-A00AFF27F984Q33981698-D3BBF931-0F27-4743-B7CC-9D4756860778Q34333286-352C200F-3EC4-4A7C-917B-BCAB9734D3DAQ34394167-C98B17CD-CB38-4A43-8C6E-700E79AD2875Q34537953-DD7394D7-2B40-4083-BEF7-15E6D5BDBE35Q34601561-27AFF4B5-588C-44C7-B5C7-0BA6074E926CQ34729771-87909526-A56E-47F5-8EE4-D737325C6D96Q35115756-FB135E4C-4096-4866-A26B-9DC8E307D00BQ35119128-58A8CA7E-5118-4A12-B7B3-71CCEE048A2AQ35120701-AF7E7861-6294-44AC-A051-BA964E792BD4Q35125533-466A1E71-80FF-49A7-B83C-DFD17C1DD126Q35125769-B840167E-8196-4944-8CF5-4C807FB3A9A6Q35129221-1A292482-75CB-40E0-8CE0-822AD61BB31DQ35279768-BFFE89B6-D3B6-493B-99E6-F7D4DA243064Q35283050-EA306F96-EDEC-40CD-9570-2E16569B6075Q35362532-AAA359F6-2751-4911-8C85-C3BF434484CAQ35809150-7F705E7E-FDD0-4D6E-829F-88D70AF836DDQ35814875-7F326835-8820-4220-8AA9-0818320EB312Q35820858-6524DF84-8CAC-4082-A90E-477127FBC759Q35846160-32717E50-C3D4-4762-9CE9-7F1A33B7EE93Q35897356-D0E65FC1-31F0-4234-9E72-2EAA98910EBAQ35899647-3E1FA214-2EC4-41EE-A8EA-23E9714BDA54Q35904010-9ACA99FA-0A2C-4D03-A157-FE0679178B12Q36505425-0C878C73-C53E-4B52-AFE4-0A148B681A4BQ36754440-6D1DA53A-6714-4B2E-B466-00D865C69C68Q36754643-BC04E6B9-0E2B-4D85-AA57-A19751EF10B9Q36754974-86794F73-566B-48D8-8BFC-A893C3655B88Q36756193-9916F1E4-AECE-4655-9B77-B1686943F7CBQ36757133-864D6AF3-907A-4D9E-81AB-B646BFA3FB02Q37053205-E8586F04-0517-40FA-A4CA-441EC5782E3BQ37834318-47731F30-6830-436F-A80B-9D3D8EED48FEQ39556591-20D3BF20-C451-425C-B21F-9FB265BC509DQ39558184-BF62F275-0A26-42E9-B269-80C7D67C5272Q39559548-14A819A4-30BE-41DF-A7B4-9C1C38D07CB4Q39779720-106D7294-C414-4757-96D2-F26976995B42Q39780025-7D1DCB16-5285-49B8-B19F-9C02DA506B8BQ39780047-2A889C19-5557-4223-963C-BC9E2B382FC4Q39782024-AC086B7B-2A6F-4094-9768-B01F62745406
P2860
Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital
description
1989 nî lūn-bûn
@nan
1989 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Widespread quinolone resistanc ...... isolates in a general hospital
@ast
Widespread quinolone resistanc ...... isolates in a general hospital
@en
type
label
Widespread quinolone resistanc ...... isolates in a general hospital
@ast
Widespread quinolone resistanc ...... isolates in a general hospital
@en
prefLabel
Widespread quinolone resistanc ...... isolates in a general hospital
@ast
Widespread quinolone resistanc ...... isolates in a general hospital
@en
P2093
P2860
P356
P1476
Widespread quinolone resistanc ...... isolates in a general hospital
@en
P2093
P2860
P304
P356
10.1128/AAC.33.4.593
P407
P577
1989-04-01T00:00:00Z